Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2021

View Archived Issues

IL-27 drives metabolic programs and its targeting aids in the treatment of obesity

FBXO22 sensitizes tumor cells to DNA damage by PD-L1 degrading

Novel syngeneic bladder cancer model using organoid line with specific gene deletions

Ube Industries patents integrin alphav antagonists

Suzhou Zelgen Biosciences synthesizes new GTPase KRAS mutant inhibitors

Glixogen Therapeutics identifies GLI1 inhibitors

Jiangsu Chia Tai Tianqing Pharmaceutical Group presents SOS1 inhibitors

Shanghai Zheye Biotechnology divulges new SGLT-1 inhibitors

RAGE-229 inhibits RAGE-DIAPH1 binding and lessens diabetic complications in mice

[68Ga]SP-94 shows excellent uptake in GRP78-positive HCC tumors

GP73 analysis aids in the diagnosis of NASH and staging of hepatic fibrosis

Targeting TWEAK shows potential as alternative therapeutic strategy for psoriasis

Oragenics reports on SARS-CoV-2 vaccine formulations in hamster challenge study

MALT1 mutant mice reveal role of E3 ligase TRAF6 in peripheral immune tolerance

Stepwise engineered IL-37-Fc-fusion protein shows improved therapeutic likeness

Small molecule allows targeted degradation of repeat expansion in vitro and in vivo in ALS models

Chimeric obtains option to license CORE-NK platform from Case Western Reserve University

DREADD approach calms neuropsychiatric dread circuits in primates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...